MedTrace Logo

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

NCT00373399 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effects of smoked marijuana on both risk taking and decision making tasks.

Conditions

  • Marijuana Use Disorder

Interventions

DRUG

Inactive Marijuana (0% THC)

Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.

DRUG

Low THC marijuana (1.8 %THC)

Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.

DRUG

High THC marijuana (3.9% THC)

Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Margaret Haney, Ph.D. · New York State Psychiatric Institute

  • Efrat Aharonovich, Ph.D. · New York State Psyhciatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-03-31
Completion
2008-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373399 on ClinicalTrials.gov